4SC-202 exerts an anti-tumor effect in cervical cancer by targeting PRLR signaling pathway

Abstract

The aim of the present study is to investigate whether 4SC-202, a selective class I histone deacetylase inhibitor (HDACi), plays an anti-tumor role in cervical cancer (CC) by targeting prolactin receptor (PRLR). CCK-8 and colony formation assays were used to evaluate the effects of 4SC-202 on the proliferation of CC cells in vitro. Effects of 4SC-202 on the cell cycle distribution and apoptosis in SiHa cells were determined by ow cytometry and western blotting, respectively. Immuno uorescence and western blotting were performed to detect the activities of PRLR-related pathways and PRLR expression in CC cells. A xenograft tumor model in nude mice was established to examine effects of 4SC-202 on the tumor growth, apoptosis and PRLR-related pathways in vivo. The biochemical analyzer and H&E staining were used to detect the serum biochemical indexes and organ toxicity. 4SC-202 inhibited the proliferation of CC cells (SiHa, HeLa, and CaSki) in vitro in a time-and dose-dependent manner. SiHa cells were treated with 1 or 5 μM 4SC-202 for 72 h and then subjected to various functional assays. The assays showed that 4SC-202 signi cantly induced G2/M phase arrest and apoptosis, while inhibiting the activities of PRLR-related pathways and PRLR expression. In addition, 4SC-202 reduced tumor growth and induced apoptosis in vivo. 4SC-202 down-regulated the expression of PRLR and activities of PRLR-related pathways in the mouse model, displayed no effects on serum biochemical indicators and caused no toxicity to mouse organs. This nding suggests that 4SC-202 may serve as a novel therapeutic agent for CC.

The Emerging Role of Histone Deacetylase Inhibitors in Cervical Cancer Therapy

“…Zhang et al investigated the role of the selective class I HDACI 4SC-202 in cervical cancer cells and reported cell cycle arrest in the G2/M phase arrest, apoptosis induction, inhibition of the prolactin receptor-related pathways, as well as tumor growth restriction in vivo [ 107 ].…”